Table II. Sample distribution according to experiments and study phase.

Region	US				South Africa
HIV status	HIV−		HIV+		HIV−		HIV+
TB status	TB−	TB+	TB−	TB+	TB−	TB+	TB−	TB+
Multiplex HD-NAPPA (n = 120)	11	21	12	8	12	5	10	41
Deconvolution (n = 94)a	6	20	6	7	6	5	6	38
Validation (n = 124)b	11	23	11	9	12	6	12	40
ELISA (n = 285)c	22	45	46	21	25	13	24	89

^a Because the deconvolution of positive reactions was the prime goal of this experiment, we focused these analyses predominantly on TB+ samples from the multiplex HD-NAPPA screening.

^b Consisting of biologically independent samples.

^c Consisting of the original screening and validation samples (n = 244) and heretofore untested samples (n = 41).